ERBB2 and breast carcinoma: The scaffold-protein-based agents [99mTc]Tc-(HE)3-G3 and [99mTc]Tc-ADAPT6 revealed the difference between clinically HER2-positive and HER2-negative breast cancer tumors [21,22].